Rocbrutinib

DRUG5 trials

Conditions

B-cell Non-Hodgkin LymphomaCLLCLL (Chronic Lymphocytic Leukemia)CLL / SLLCLL ProgressionCLL, RefractoryCLL, RelapsedDiffuse Large B-Cell Lymphoma (DLBCL)

Phase 1

Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma

RecruitingNCT06251180

Guangzhou Lupeng Pharmaceutical Company LTD.B-cell Non-Hodgkin Lymphoma

Start: 2024-04-10End: 2029-12-31Target: 112Updated: 2025-03-25

Phase 2

A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

Active, not recruitingNCT05716087

Guangzhou Lupeng Pharmaceutical Company LTD.Mantle Cell Lymphoma (MCL)

Start: 2023-02-21End: 2026-06-30Target: 62Updated: 2026-01-15

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

RecruitingNCT07189065

Guangzhou Lupeng Pharmaceutical Company LTD.Diffuse Large B-Cell Lymphoma (DLBCL)

Start: 2025-11-27End: 2028-12-31Target: 150Updated: 2025-12-16

Phase 3

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Not yet recruitingNCT07342478

Newave Pharmaceutical IncCLL, CLL (Chronic Lymphocytic Leukemia), CLL Progression +5

Start: 2026-01-30End: 2030-07-30Target: 306Updated: 2026-01-16

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

RecruitingNCT07377578

Guangzhou Lupeng Pharmaceutical Company LTD.Mantle Cell Lymphoma

Start: 2026-02-05End: 2033-01-30Target: 394Updated: 2026-02-06

Related Papers

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Blood2025-11-03

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood2024-11-05

An open label, single arm, multicenter phase II study of the efficacy and safety of LP-168 monotherapy for relapsed or refractory mantle cell lymphoma.

Journal of Clinical Oncology2024-06-01

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood2023-11-02